Clinical trial
LACunar Intervention (LACI-2) Trial-2: Assessment of Safety and Efficacy of Cilostazol and Isosorbide Mononitrate to Prevent Recurrent Lacunar Stroke and Progression of Cerebral Small Vessel Disease.
NCT03451591 is registered in ClinicalTrials.gov with University of Edinburgh as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- LACunar Intervention (LACI-2) Trial-2: Assessment of Safety and Efficacy of Cilostazol and Isosorbide Mononitrate to Prevent Recurrent Lacunar Stroke and Progression of Cerebral Small Vessel Disease.
- Lead sponsor
- University of Edinburgh
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- January 8, 2018
- Completion date
- August 11, 2022
- Enrollment
- 363 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.